Mar 21, 2023 / NTS GMT
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello, and welcome to the BioSyent, Inc. Q4 and Full Year Fiscal 2022 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company. Before I start the presentation, I want to bring your attention to our disclaimer on forward-looking statements. And I'll jump right into the presentation by looking at the Q4 revenue, EBITDA and net income after tax.
So you can see sales were just short of $7.5 million for the quarter. That was up 3% to the year ago. And I want to go into a little bit of detail to help you follow the moving parts on revenue. So in the quarter, the Canadian Pharmaceutical business was up 13% to the year ago. The International Pharma business down 63%, and the Legacy Business down 87% in the quarter. You'll recall that late last year, we discontinued products effective the beginning of 2022, I should say late last year as in 2021, the comparable period. And so when we're looking at revenue for Canada and overall, it is useful to also compare to a continuing business basis. And
Q4 2022 Biosyent Inc Earnings Call Transcript
Mar 21, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers